Financial Survey: Bolt Biotherapeutics (NASDAQ:BOLT) versus Universe Pharmaceuticals (NYSE:UPC)

Universe Pharmaceuticals (NYSE:UPC) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Earnings and Valuation

This table compares Universe Pharmaceuticals and Bolt Biotherapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$32.31 million	0.25	-$6.16 million	N/A	N/A
Bolt Biotherapeutics	$7.88 million	5.42	-$69.20 million	($1.83)	-0.61

Universe Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics.

Profitability

This table compares Universe Pharmaceuticals and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Bolt Biotherapeutics	-878.58%	-51.18%	-37.81%

Institutional and Insider Ownership

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Universe Pharmaceuticals and Bolt Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	0	0	0	0	N/A
Bolt Biotherapeutics	0	0	2	0	3.00

Bolt Biotherapeutics has a consensus price target of $7.00, suggesting a potential upside of 525.00%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Universe Pharmaceuticals.

Volatility & Risk

Universe Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Summary

Universe Pharmaceuticals beats Bolt Biotherapeutics on 7 of the 11 factors compared between the two stocks.

About Universe Pharmaceuticals

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.